Compare Cadila Healthcare with Biocon Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs BIOCON - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

BIOCON  
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE BIOCON CADILA HEALTHCARE/
BIOCON
 
P/E (TTM) x 14.1 19.5 72.2% View Chart
P/BV x 2.7 3.0 91.0% View Chart
Dividend Yield % 1.5 0.4 388.8%  

Financials

 CADILA HEALTHCARE   BIOCON
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
BIOCON
Mar-18
CADILA HEALTHCARE/
BIOCON
5-Yr Chart
Click to enlarge
High Rs5581,188 47.0%   
Low Rs362305 118.5%   
Sales per share (Unadj.) Rs116.368.7 169.2%  
Earnings per share (Unadj.) Rs17.97.6 236.6%  
Cash flow per share (Unadj.) Rs23.114.0 165.6%  
Dividends per share (Unadj.) Rs3.501.00 350.0%  
Dividend yield (eoy) %0.80.1 568.3%  
Book value per share (Unadj.) Rs85.486.3 98.9%  
Shares outstanding (eoy) m1,023.74600.00 170.6%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x4.010.9 36.4%   
Avg P/E ratio x25.798.9 26.0%  
P/CF ratio (eoy) x19.953.4 37.2%  
Price / Book Value ratio x5.48.6 62.3%  
Dividend payout %19.613.2 147.9%   
Avg Mkt Cap Rs m470,664447,900 105.1%   
No. of employees `00011.86.1 192.2%   
Total wages/salary Rs m18,5459,311 199.2%   
Avg. sales/employee Rs Th10,072.76,705.8 150.2%   
Avg. wages/employee Rs Th1,569.11,514.2 103.6%   
Avg. net profit/employee Rs Th1,547.7736.9 210.0%   
INCOME DATA
Net Sales Rs m119,04941,234 288.7%  
Other income Rs m1,1322,062 54.9%   
Total revenues Rs m120,18143,296 277.6%   
Gross profit Rs m28,4758,291 343.4%  
Depreciation Rs m5,3883,851 139.9%   
Interest Rs m911615 148.1%   
Profit before tax Rs m23,3085,887 395.9%   
Minority Interest Rs m628213 294.8%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,6441,569 359.7%   
Profit after tax Rs m18,2924,531 403.7%  
Gross profit margin %23.920.1 119.0%  
Effective tax rate %24.226.7 90.9%   
Net profit margin %15.411.0 139.8%  
BALANCE SHEET DATA
Current assets Rs m82,00541,486 197.7%   
Current liabilities Rs m60,72021,413 283.6%   
Net working cap to sales %17.948.7 36.7%  
Current ratio x1.41.9 69.7%  
Inventory Days Days7364 114.3%  
Debtors Days Days9894 104.4%  
Net fixed assets Rs m83,70350,661 165.2%   
Share capital Rs m1,0243,000 34.1%   
"Free" reserves Rs m86,42148,808 177.1%   
Net worth Rs m87,44551,808 168.8%   
Long term debt Rs m25,55117,898 142.8%   
Total assets Rs m180,65399,897 180.8%  
Interest coverage x26.610.6 251.5%   
Debt to equity ratio x0.30.3 84.6%  
Sales to assets ratio x0.70.4 159.7%   
Return on assets %10.65.2 206.4%  
Return on equity %20.98.7 239.2%  
Return on capital %22.09.6 228.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,68312,058 354.0%   
Fx outflow Rs m11,2427,348 153.0%   
Net fx Rs m31,4414,710 667.5%   
CASH FLOW
From Operations Rs m9,1936,621 138.8%  
From Investments Rs m-9,737-6,840 142.4%  
From Financial Activity Rs m515-2,397 -21.5%  
Net Cashflow Rs m-29-2,612 1.1%  

Share Holding

Indian Promoters % 74.8 40.4 185.1%  
Foreign collaborators % 0.0 20.6 -  
Indian inst/Mut Fund % 8.3 8.4 98.8%  
FIIs % 5.9 10.7 55.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 19.9 55.3%  
Shareholders   44,069 109,995 40.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   GSK PHARMA  JUBILANT LIFE SCIENCES  DISHMAN PHARMA  PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 292 Points Higher; Automobile and Metal Stocks Witness Buying(Closing)

After opening the day marginally higher, Indian share markets witnessed buying interest throughout the day and ended on a strong note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Oct 15, 2019 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS